- Home
- RVPH vs JZXN Comparison
RVPH vs JZXN Comparison
Compare RVPH & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- JZXN
- Stock Information
- Founded
- RVPH 2006
- JZXN 2019
- Country
- RVPH United States
- JZXN China
- Employees
- RVPH N/A
- JZXN N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- JZXN Retail-Auto Dealers and Gas Stations
- Sector
- RVPH Health Care
- JZXN Consumer Discretionary
- Exchange
- RVPH Nasdaq
- JZXN Nasdaq
- Market Cap
- RVPH 32.8M
- JZXN N/A
- IPO Year
- RVPH N/A
- JZXN 2021
- Fundamental
- Price
- RVPH $0.37
- JZXN $1.03
- Analyst Decision
- RVPH Strong Buy
- JZXN
- Analyst Count
- RVPH 5
- JZXN 0
- Target Price
- RVPH $9.00
- JZXN N/A
- AVG Volume (30 Days)
- RVPH 2.6M
- JZXN 488.4K
- Earning Date
- RVPH 08-13-2025
- JZXN 03-03-2025
- Dividend Yield
- RVPH N/A
- JZXN N/A
- EPS Growth
- RVPH N/A
- JZXN N/A
- EPS
- RVPH N/A
- JZXN N/A
- Revenue
- RVPH N/A
- JZXN $1,400,139.00
- Revenue This Year
- RVPH N/A
- JZXN N/A
- Revenue Next Year
- RVPH N/A
- JZXN N/A
- P/E Ratio
- RVPH N/A
- JZXN N/A
- Revenue Growth
- RVPH N/A
- JZXN N/A
- 52 Week Low
- RVPH $0.30
- JZXN $0.84
- 52 Week High
- RVPH $4.28
- JZXN $7.82
- Technical
- Relative Strength Index (RSI)
- RVPH 30.28
- JZXN 30.41
- Support Level
- RVPH $0.35
- JZXN $0.85
- Resistance Level
- RVPH $0.83
- JZXN $1.70
- Average True Range (ATR)
- RVPH 0.07
- JZXN 0.30
- MACD
- RVPH -0.04
- JZXN -0.00
- Stochastic Oscillator
- RVPH 11.32
- JZXN 9.31
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.